Evidence map›Paper›PMID 34585048›Full record

ReviewAnnals of gastroenterological surgery2021

Optimal patient selection for successful two-stage hepatectomy of bilateral colorectal liver metastases.

Katsunori Imai, Marc-Antoine Allard, Hideo Baba, René Adam

Open access · goldAbstract readReview
In one paragraph

Review in Annals of gastroenterological surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Katsunori ImaiCentre Hépato-Biliaire AP-HP Hôpital Universitaire Paul Brousse Villejuif France.ORCID https://orcid.org/0000-0003-0549-1825
Marc-Antoine AllardCentre Hépato-Biliaire AP-HP Hôpital Universitaire Paul Brousse Villejuif France.
Hideo BabaDepartment of Gastroenterological Surgery Graduate School of Life Sciences Kumamoto University Kumamoto Japan.ORCID https://orcid.org/0000-0002-3474-2550
René AdamCentre Hépato-Biliaire AP-HP Hôpital Universitaire Paul Brousse Villejuif France.
Hôpital Paul-Brousse · FRKumamoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two-stage hepatectomy (TSH) is one of the specific surgical techniques that can expand the pool of resectable patients with initially unresectable colorectal liver metastases (CRLM). The indication of TSH for CRLM is only bilateral, multinodular disease, which cannot be resected by a single hepatectomy. TSH is nowadays considered an effective treatment for selected patients, with acceptable morbidity/mortality rates and promising long-term outcomes. However, not all eligible patients can benefit from the TSH strategy. One of the most important issues is dropout from the strategy (failure to complete both of the two sequential procedures), because the survival of such patients is drastically worse compared with patients who can complete both stages. Another important issue is the early recurrence rate and subsequent poor survival even after completion of TSH. Thus, the selection of appropriate patients who can really benefit from the TSH strategy is crucial. This review discusses the optimal patient selection for TSH, which should be helpful for the development of treatment strategies for patients with extensive CRLM.

Indexed as

colorectal liver metastasespatient selectiontwo‐stage hepatectomy

Identifiers

PMID34585048
PMCPMC8452472
OpenAlexW3158308600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.